pSivida Limited Release: Positive European Trial Results For Retisert(TM)

PERTH, Australia & BOSTON--(BUSINESS WIRE)--April 6, 2006--Global bio-nanotech company pSivida Limited (Nasdaq:PSDV - News; ASX:PSD - News; GER:PSI) today announced that global eye health company Bausch & Lomb (NYSE:BOL - News) recently released two year results from their European clinical trial of Retisert(TM) for the treatment of chronic non-infectious posterior segment uveitis. Bausch & Lomb, exclusive licensee of Retisert(TM), conducted the randomized study that showed the recurrence rate for uveitis was significantly lower in eyes receiving Retisert(TM) than in eyes receiving standard of care (systemic corticosteroid or other immunosuppressive agents). The study involved 146 patients across ten countries in Europe and the Middle East.

Back to news